MSD strengthens commercial capabilities with commitment to Veeva Vault CRM ahead of major launches
-
Global pharma leader MSD (Merck outside the US and Canada) commits to Veeva Vault CRM, strengthening their strategic partnership ahead of a major product launch phase.
- The Vault CRM platform will provide MSD with a robust foundation to streamline commercial execution across diverse therapeutic areas and modalities.
Veeva Systems today (July 22, 2025) announced that Merck, (known as MSD outside the United States and Canada), has chosen Veeva Vault CRM to support its upcoming commercial operations.
The Vault CRM solution will underpin MSD’s commercial strategy during a critical phase of new product launches, spanning diverse therapeutic areas and innovative modalities. This commitment signals an expansion of the strategic partnership between MSD and Veeva, aimed at driving customer engagement and execution excellence.
Dave Williams, executive vice president and chief information and digital officer at MSD, said: “We are excited to expand our strategic partnership with Veeva by moving to Vault CRM. We share a deep commitment to customer success, and Vault CRM will provide MSD the technology foundation to drive commercial execution.”
Veeva CEO Peter Gassner added: “MSD has consistently been at the forefront of leading-edge science that improves the lives of millions around the world. We are honored to be a strategic partner to MSD, and it is great to see our partnership extend to Vault CRM.”
Vault CRM is a core component of the Vault CRM Suite, a set of advanced applications designed to optimize commercial execution through both personal and digital channels. With global capabilities tailored to meet regional and country-specific business and compliance demands, Vault CRM equips pharmaceutical companies like MSD with the tools to accelerate customer engagement and commercial success.
As MSD gears up for this landmark launch period, Vault CRM is set to be a critical asset in enabling agile, compliant, and data-driven commercial operations, strengthening MSD’s ability to deliver innovative therapies to patients worldwide.
